Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells
- 15 March 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (6) , 2234-2242
- https://doi.org/10.1158/0008.5472.can-04-2781
Abstract
Elevated levels of the bioactive lipid lysophosphatidic acid (LPA) are detectable in the majority of patients with both early- and late-stage ovarian cancer, suggesting that LPA promotes early events in ovarian carcinoma dissemination. LPA contributes to the development, progression, and metastasis of ovarian cancer in part by inducing the expression of genes that contribute to proliferation, survival, or invasion, including cyclooxgenase-2 (COX-2) and matrix metalloproteinase-2 (MMP-2). We have previously shown that LPA promotes proMMP-2 activation and MMP-2-dependent migration and invasion in ovarian cancer cells. The purpose of the current study was to determine whether the effect of LPA on acquisition of the metastatic phenotype in ovarian cancer cells is mediated via a COX-2-dependent mechanism. Immunohistochemical analysis of 173 ovarian tumors showed strong COX-2 immunoreactivity in 63% of tumor specimens, including 50% of borderline tumors. LPA increased COX-2 protein expression in a time- and concentration-dependent manner in two of three immortalized borderline ovarian epithelial cells as well as in four of six ovarian cancer cell lines. This was accomplished by both activation of the Edg/LPA receptor and LPA-mediated transactivation of the epidermal growth factor receptor, which increased COX-2 expression via the Ras/mitogen-activated protein kinase pathway. COX-2 also played a role in LPA-induced invasion and migration, as treatment with the COX-2 specific inhibitor NS-398 reduced LPA-induced proMMP-2 protein expression and activation and blocked MMP-dependent motility and invasive activity. These data show that COX-2 functions as a downstream mediator of LPA to potentiate aggressive cellular behavior.Keywords
This publication has 62 references indexed in Scilit:
- Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interferenceOncogene, 2003
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Prostaglandin E2 Promotes Integrin αVβ3-dependent Endothelial Cell Adhesion, Rac-activation, and Spreading through cAMP/PKA-dependent SignalingJournal of Biological Chemistry, 2002
- Cyclooxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian CancerGynecologic Oncology, 2002
- Epidermal Growth Factor Receptor Signaling and the Invasive Phenotype of Ovarian Carcinoma CellsJNCI Journal of the National Cancer Institute, 2001
- Lysophospholipids Increase Interleukin-8 Expression in Ovarian Cancer CellsGynecologic Oncology, 2001
- Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cellsInternational Journal of Cancer, 2000
- Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient MicePublished by Elsevier ,1997
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970